Hansa Biopharma AB (publ)

LSE:0RC7 Stock Report

Market Cap: SEK 1.8b

Hansa Biopharma Valuation

Is 0RC7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RC7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 12.34
Fair Value
112.3% overvalued intrinsic discount
3
Number of Analysts

Below Fair Value: 0RC7 (SEK26.2) is trading above our estimate of fair value (SEK12.34)

Significantly Below Fair Value: 0RC7 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RC7?

Key metric: As 0RC7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RC7. This is calculated by dividing 0RC7's market cap by their current revenue.
What is 0RC7's PS Ratio?
PS Ratio9.7x
SalesSEK 181.68m
Market CapSEK 1.76b

Price to Sales Ratio vs Peers

How does 0RC7's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RC7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5x
BVXP Bioventix
10.9xn/aUK£148.9m
AVCT Avacta Group
5.6x-26.96%UK£125.6m
OXB Oxford Biomedica
2.4x16.52%UK£314.3m
TRX Tissue Regenix Group
1xn/aUK£23.2m
0RC7 Hansa Biopharma
9.7x42.23%SEK 1.8b

Price-To-Sales vs Peers: 0RC7 is expensive based on its Price-To-Sales Ratio (9.7x) compared to the peer average (5x).

Price to Sales Ratio vs Industry

How does 0RC7's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
2.1x3.85%US$1.85b
OXB Oxford Biomedica
2.4x16.52%US$418.36m
TRX Tissue Regenix Group
1xn/aUS$30.82m
AREC Arecor Therapeutics
2.9x-11.64%US$19.35m
0RC7 9.7xIndustry Avg. 7.4xNo. of Companies8PS020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RC7 is expensive based on its Price-To-Sales Ratio (9.7x) compared to the European Biotechs industry average (7.4x).

Price to Sales Ratio vs Fair Ratio

What is 0RC7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RC7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.7x
Fair PS Ratio8.8x

Price-To-Sales vs Fair Ratio: 0RC7 is expensive based on its Price-To-Sales Ratio (9.7x) compared to the estimated Fair Price-To-Sales Ratio (8.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RC7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 26.20
SEK 95.00
+262.60%
48.99%SEK 143.00SEK 32.00n/a3
May ’26SEK 26.44
SEK 95.00
+259.30%
48.99%SEK 143.00SEK 32.00n/a3
Apr ’26SEK 22.52
SEK 85.25
+278.55%
55.39%SEK 143.00SEK 32.00n/a4
Mar ’26SEK 26.16
SEK 91.25
+248.81%
45.17%SEK 143.00SEK 46.00n/a4
Feb ’26SEK 34.34
SEK 101.75
+196.30%
52.39%SEK 175.00SEK 46.00n/a4
Jan ’26SEK 39.08
SEK 101.75
+160.36%
52.39%SEK 175.00SEK 46.00n/a4
Dec ’25SEK 31.84
SEK 99.25
+211.71%
52.54%SEK 175.00SEK 46.00n/a4
Nov ’25SEK 36.54
SEK 100.00
+173.67%
51.53%SEK 175.00SEK 46.00n/a4
Oct ’25SEK 39.12
SEK 100.00
+155.62%
51.53%SEK 175.00SEK 46.00n/a4
Sep ’25SEK 55.40
SEK 100.00
+80.51%
51.53%SEK 175.00SEK 46.00n/a4
Aug ’25SEK 40.20
SEK 100.00
+148.76%
51.53%SEK 175.00SEK 46.00n/a4
Jul ’25SEK 46.18
SEK 105.00
+127.37%
44.67%SEK 175.00SEK 57.00n/a4
Jun ’25SEK 49.60
SEK 105.00
+111.69%
44.67%SEK 175.00SEK 57.00n/a4
May ’25SEK 28.64
SEK 105.00
+266.62%
44.67%SEK 175.00SEK 57.00SEK 26.444
Apr ’25SEK 29.10
SEK 112.50
+286.60%
36.87%SEK 174.00SEK 57.00SEK 22.524
Mar ’25SEK 31.71
SEK 112.50
+254.73%
36.87%SEK 174.00SEK 57.00SEK 26.164
Feb ’25SEK 35.69
SEK 91.00
+154.97%
57.96%SEK 173.00SEK 16.00SEK 34.345
Jan ’25SEK 26.79
SEK 108.33
+304.34%
57.06%SEK 195.00SEK 16.00SEK 39.086
Dec ’24SEK 25.50
SEK 123.00
+382.35%
47.34%SEK 195.00SEK 16.00SEK 31.846
Nov ’24SEK 23.10
SEK 123.00
+432.47%
47.34%SEK 195.00SEK 16.00SEK 36.546
Oct ’24SEK 34.40
SEK 167.50
+386.97%
22.45%SEK 224.00SEK 109.00SEK 39.126
Sep ’24SEK 44.28
SEK 167.50
+278.27%
22.45%SEK 224.00SEK 109.00SEK 55.406
Aug ’24SEK 54.07
SEK 167.50
+209.78%
22.45%SEK 224.00SEK 109.00SEK 40.206
Jul ’24SEK 42.51
SEK 168.50
+296.38%
23.79%SEK 224.00SEK 112.00SEK 46.186
Jun ’24SEK 46.18
SEK 168.50
+264.91%
23.79%SEK 224.00SEK 112.00SEK 49.606
May ’24SEK 50.21
SEK 171.29
+241.15%
19.80%SEK 224.00SEK 128.00SEK 28.647
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
SEK 95.95
Fair Value
72.7% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 11:39
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hansa Biopharma AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Christian LeeABG Sundal Collier Sponsored
Madhu KumarB. Riley Securities, Inc.